AXT Inc. (AXTI) is a compound semiconductor substrate maker that has spent the past three years grinding through a painful revenue downcycle — sales fell roughly 14.5% per year on a three-year basis from their 2022 peak, margins collapsed deep into negative territory, and the company has been burning cash at the operating level. The good news is that the most recent quarter (Q1 2026) flashed a genuine turnaround signal: gross margin nearly tripled year-over-year to nearly 30%, EBITDA turned positive for the first time in several quarters, and capital spending has been reined in sharply. AXT enters this potential recovery with almost no debt, a current ratio comfortably above 2.5, and a leaner cost structure — but sustained profitability still depends on whether revenue can climb back toward the $130–140 million range where the business historically generates healthy returns.
Snapshot & Big Picture
AXT manufactures indium phosphide, gallium arsenide, and germanium substrates — specialty wafers used in data center lasers, 5G chips, solar cells, and other high-performance electronics. The business is highly cyclical and operationally leveraged: when volumes are high, margins expand quickly; when demand softens, losses mount fast. Revenue peaked at $141 million in 2022, then fell for two consecutive years to a trough of $75.8 million in 2023 before partially recovering to $99.4 million in 2024. The fiscal year ending December 2025 saw revenue slide again to $88.3 million, suggesting the recovery is uneven. However, the Q1 2026 quarterly print of $26.9 million annualizes to roughly $108 million, and profitability metrics in that quarter showed dramatic sequential improvement — indicating momentum may be building again.
| Fiscal Year | Revenue | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|---|
| 2016 | $81.3M | 32.4% | 7.9% | 6.9% |
| 2017 | $98.7M | 34.9% | 12.8% | 10.3% |
| 2018 | $102.4M | 36.2% | 11.9% | 9.4% |
| 2019 | $83.3M | 29.8% | -0.4% | -3.1% |
| 2020 | $95.4M | 31.7% | 4.1% | 3.4% |
| 2021 | $137.4M | 34.5% | 9.4% | 10.6% |
| 2022 | $141.1M | 36.9% | 8.9% | 11.2% |
| 2023 | $75.8M | 17.6% | -28.5% | -23.6% |
| 2024 | $99.4M | 24.0% | -14.9% | -11.7% |
| 2025 | $88.3M | 12.7% | -24.9% | -24.1% |
Latest Quarter Snapshot (Q1 2026 — Most Current Data)
The quarter ended March 31, 2026 is more recent than any annual filing and offers the clearest read on where the business stands today. Revenue came in at $26.9 million, gross margin recovered sharply to 29.6%, and EBITDA turned modestly positive at $850,000. The operating margin was still slightly negative at -5.9% and the net margin was -6.0%, but both represent a massive improvement over the deeply negative annual figures for 2025. The current ratio strengthened to 2.59, and debt-to-equity remained negligible at 0.019. Capital expenditures were $1.4 million for the quarter, a capex-to-revenue ratio of about 5.1% — suggesting the company is no longer in heavy investment mode and is preserving cash while demand recovers.
| Metric | Q1 2026 (Quarter ended Mar 31, 2026) |
|---|---|
| Revenue | $26.9M |
| EBITDA | $850K (positive) |
| Gross Margin | 29.6% |
| Operating Margin | -5.9% |
| Net Margin | -6.0% |
| Current Ratio | 2.59 |
| Debt-to-Equity | 0.019 |
| Capital Expenditures | $1.4M (5.1% of revenue) |
Profitability
AXT's profitability history tells a clear story of boom, bust, and cautious recovery. From 2016 through 2022, the company maintained gross margins in the 30–37% range and generated positive operating and net income in most years. The 2023 revenue collapse — driven by inventory destocking across the semiconductor supply chain — cratered gross margin to 17.6% and pushed operating margin to -28.5%. A partial revenue rebound in 2024 lifted gross margins back toward 24%, but fiscal 2025 was a setback: despite modest revenue, gross margin fell all the way to 12.7%, the worst in the dataset, pointing to unfavorable product mix or pricing pressure during the year. The Q1 2026 gross margin of 29.6% is therefore an encouraging signal that the worst may be over, though full-year profitability restoration requires sustained revenue at or above the $100 million level based on historical cost structures. EBITDA was negative in 2023, 2024, and 2025 — the first multi-year stretch of EBITDA losses in this dataset — before turning positive in Q1 2026.
Financial Health & Capital Expenditures
AXT's balance sheet remains conservatively positioned. The current ratio has stayed above 2.0 throughout the downcycle, reaching 2.59 in Q1 2026. Debt-to-equity is essentially zero (0.019 most recently), meaning the company is not leveraged — a meaningful buffer during a period of operational losses. The debt-to-equity figure was not reported (shown as null) in filings from 2016 through 2023, likely reflecting minimal or no long-term debt on the balance sheet in those periods.
Capital expenditure trends are one of the more interesting features of this dataset. During the growth years of 2018–2022, AXT invested aggressively in capacity — capex ran as high as $40.5 million (39.6% of revenue) in 2018 and $28.5 million (20.2% of revenue) in 2022. As the downcycle hit, management sharply curtailed investment: capex fell to $10.5 million in 2023, $5.8 million in 2024, and $6.0 million in 2025. On a trailing quarterly basis in Q1 2026, capex was just $1.4 million (5.1% of revenue). This dramatic reduction in capital intensity suggests AXT is running on previously built-out capacity and conserving liquidity — a prudent move during a cyclical trough, though it also means any significant demand surge could eventually require a new round of investment spending.
| Period | Capital Expenditures | Capex / Revenue |
|---|---|---|
| FY 2018 | $40.5M | 39.6% |
| FY 2019 | $21.8M | 26.2% |
| FY 2020 | $19.9M | 20.8% |
| FY 2021 | $29.6M | 21.6% |
| FY 2022 | $28.5M | 20.2% |
| FY 2023 | $10.5M | 13.8% |
| FY 2024 | $5.8M | 5.8% |
| FY 2025 | $6.0M | 6.8% |
| Q1 2026 | $1.4M | 5.1% |
Growth
The revenue CAGR figures across available windows paint a sobering picture of the post-peak contraction, though the five-year figure tempers that somewhat by anchoring to the 2020 trough.
| Window | Start Year (Revenue) | End Year (Revenue) | CAGR |
|---|---|---|---|
| 3-Year | FY 2022 ($141.1M) | FY 2025 ($88.3M) | -14.5% |
| 5-Year | FY 2020 ($95.4M) | FY 2025 ($88.3M) | -1.5% |
| 10-Year | N/A | N/A | Not available — SEC filing history in this dataset does not extend back 10 fiscal years from 2025 |
The three-year CAGR of -14.5% reflects the severity of the 2022–2025 revenue contraction from the cycle peak. The five-year CAGR of -1.5% is far less alarming — essentially flat — because the 2020 starting point was itself a mid-cycle year rather than a peak, which illustrates just how cyclical this business is. Neither figure suggests structural long-term growth momentum, which means AXT's investment case rests primarily on a cyclical recovery thesis rather than a secular growth story — at least until revenue can convincingly surpass prior peaks on a sustained basis.
Leave a Comment